Effects of Oral Ingestion of Drinking Water Using a Tumbler That Emits Far Infrared Rays on Metabolic Profile

Metabolic Problems Clinical Trial

Official title:

Effects of Oral Ingestion of Drinking Water Using a Tumbler That Emits Far Infrared Rays at Room Temperature on Metabolic Profile in Adults: a RCT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03920436
• Other study ID #: 02-2018-035
• Status: Completed
• Phase: N/A
• Start date: February 1, 2019
• Est. completion date: July 31, 2019

Study information

• Verified date: September 2019
• Source: Pusan National University Yangsan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays at room temperature on metabolic profile in adults for 8 weeks.

Description:

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays at room temperature on metabolic profile in adults for 8 weeks; the safety of the compound are also evaluate. The Investigators examine lipid profile, glucose, liver and renal function at baseline, as well as after 4, 8 weeks of intervention. Thirty adults were administered either 1.8 L of drinking water using a tumbler that emits far infrared rays at room temperature or drinking water using a sham-tumbler each day for 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 31, 2019
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• 19 years and older

Exclusion Criteria:

• aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than twice the highest reference value

• serum creatinine = 1.5 mg/dL)

• uncontrolled diabetes mellitus (a fasting glucose of >160 mg/dL)

• uncontrolled hypertension (BP > 160/100 mmHg)

• severe gastrointestinal symptoms

• alcohol abuser

• pregnant or lactating women

• allergic to the ingredient involved

• cardiocebrovascular diseases or any cancer during the six months prior to study

• smoker

Related Conditions & MeSH terms

• Metabolic Problems

Intervention

Dietary Supplement:
• infrared water group
This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
• sham group
This group takes 1,8 L of drinking water using a tumbler at room temperature.

Locations

Country	Name	City	State
Korea, Republic of	Pusan National University Yangsan Hospital	Yangsan	Gyeungsangnam-do

Sponsors (1)

Lead Sponsor	Collaborator
Pusan National University Yangsan Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Low density lipoprotein cholesterol (LDL-C)	Change of LDL-C during 8 weeks	Change from baseline level of LDL-C at 8 weeks
Secondary	aspartate transaminase (AST)	Change of AST during 8 weeks	Change from baseline level of AST at 8 weeks
Secondary	creatinine	Change of creatinine during 8 weeks	Change from baseline level of creatinine at 8 weeks
Secondary	homeostasis model assessment of insulin resistance (HOMA-IR)	Change of HOMA-IR during 8 weeks	Change from baseline level of HOMA-IR at 8 weeks
Secondary	body weight	Change of body weight during 8 weeks	Change from baseline level at 8 weeks
Secondary	free fatty acid	Change of free fatty acid during 8 weeks	Change from baseline level at 8 weeks
Secondary	alanine transaminase (ALT)	Change of ALT during 8 weeks	Change from baseline level of ALT at 8 weeks